US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
Portfolio Pulse from Vandana Singh
The CDC has released over 77,000 additional doses of Beyfortus, an RSV drug developed by Sanofi and AstraZeneca, due to surging demand. Beyfortus was FDA-approved in July for preventing RSV in newborns and infants. The CDC and FDA are working to ensure availability for the rest of the year and early 2024. RSV cases have notably increased, with significant hospitalizations among children under five. Shares of AstraZeneca and Sanofi rose by 0.67% on the news.
November 17, 2023 | 6:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's stock may experience a short-term positive impact following the CDC's distribution of additional Beyfortus doses, showcasing the drug's high demand and the company's role in addressing a significant health issue.
The CDC's action to distribute more doses of Beyfortus, co-developed by AstraZeneca, indicates a robust demand for the drug. This could translate into higher sales and a positive perception among investors, potentially boosting AZN's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sanofi's stock may see a positive short-term impact due to the CDC's release of additional doses of Beyfortus, indicating strong demand and ongoing support from health authorities.
The release of additional doses by the CDC reflects a strong demand for Beyfortus, which could lead to increased revenues for Sanofi. The positive news is likely to be well-received by investors, potentially leading to a short-term uptick in SNY's stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80